Restless legs syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sun, 31 May 2026 04:02:47 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Restless legs syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Intravenous ferric carboxymaltose for drug‑resistant restless legs syndrome: a randomized delayed‑start trial in adults https://clinicaltrials.eu/trial/intravenous-ferric-carboxymaltose-for-drug-resistant-restless-legs-syndrome-a-randomized-delayed-start-trial-in-adults/ Sun, 31 May 2026 04:02:47 +0000 https://clinicaltrials.eu/trial/intravenous-ferric-carboxymaltose-for-drug-resistant-restless-legs-syndrome-a-randomized-delayed-start-trial-in-adults/ The study focuses on people with drug‑resistant Restless legs syndrome, a condition that causes uncomfortable sensations in the legs and a strong urge to move them, especially during periods of rest or sleep. The treatment being tested is an infusion of ferric carboxymaltose, a form of iron that is given through a vein, and it is compared with the usual care that follows current recommendations. The purpose of the study is to determine whether this iron infusion can lessen the severity of the leg symptoms.

Participants are randomly placed into two groups: one receives the iron infusion soon after the first visit, while the other group waits for a short period before receiving the same infusion. All participants complete a questionnaire about their leg symptoms, sleep quality, mood, and daily functioning at the start of the study and again after about three months. Simple blood tests are done to check iron levels, and a brief overnight sleep recording may be performed to assess sleep patterns. The study follows each person for several months to see how the symptoms change after the treatment.

]]> Study on Pramipexole for Treating Restless Legs in Women with X-linked Adrenoleukodystrophy https://clinicaltrials.eu/trial/study-on-pramipexole-for-treating-restless-legs-in-women-with-x-linked-adrenoleukodystrophy/ Wed, 29 Apr 2026 15:03:03 +0000 https://clinicaltrials.eu/trial/study-on-pramipexole-for-treating-restless-legs-in-women-with-x-linked-adrenoleukodystrophy/ This clinical trial is focused on studying the effects of a medication called Pramipexole Viatris on women with a rare genetic condition known as X-linked adrenoleukodystrophy (X-ALD). This condition can lead to various symptoms, including issues with leg movement, often referred to as restless legs syndrome (RLS). The purpose of the study is to explore how common RLS is in women with X-ALD and to see if the medication can help improve symptoms related to leg movement, sleep, and walking.

Participants in the study will take the medication in the form of a tablet, which is taken orally. The study will last for a period of up to 16 weeks. During this time, researchers will monitor changes in sleep patterns, mood, and overall quality of life. The study will also assess how the medication affects the ability to walk and perform daily activities. Some participants may receive a placebo instead of the actual medication to help compare the effects.

The trial aims to gather valuable information that could lead to better treatment options for women with X-ALD who experience restless legs. By understanding the impact of Pramipexole Viatris on these symptoms, researchers hope to improve the quality of life for those affected by this condition. The study is expected to conclude by the end of 2025.

]]> Study on the Effects of Dextromethadone Hydrochloride for Patients with Moderate to Very Severe Restless Legs Syndrome https://clinicaltrials.eu/trial/study-on-the-effects-of-dextromethadone-hydrochloride-for-patients-with-moderate-to-very-severe-restless-legs-syndrome/ Wed, 29 Apr 2026 14:56:42 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-dextromethadone-hydrochloride-for-patients-with-moderate-to-very-severe-restless-legs-syndrome/ This clinical trial is focused on studying the effects of a medication called REL-1017, which contains the active ingredient dextromethadone hydrochloride. The study is aimed at individuals with Restless Legs Syndrome (RLS), a condition that causes an uncontrollable urge to move the legs, often accompanied by uncomfortable sensations. The trial will explore how effective, safe, and tolerable this medication is for people experiencing moderate to very severe symptoms of RLS, which may also include periodic limb movements during sleep.

The purpose of the study is to compare the effects of REL-1017 with a placebo over a period of 30 days. Participants will take a daily dose of 25 mg of the medication. The study will involve several assessments to monitor changes in RLS symptoms and sleep patterns. These assessments will take place at the beginning of the study, after 10 days, and at the end of the 30-day treatment period. The goal is to determine if the medication can significantly reduce the severity of RLS symptoms and improve sleep quality.

Throughout the study, participants will be monitored to ensure their safety and to evaluate how well they tolerate the medication. The trial is designed to provide valuable insights into the potential benefits of REL-1017 for individuals suffering from RLS, with the hope of finding a new treatment option for this challenging condition.

]]> Study on the Effects of Ferric Derisomaltose and Dopaminergic Therapy for Patients with Restless Legs Syndrome https://clinicaltrials.eu/trial/study-on-the-effects-of-ferric-derisomaltose-and-dopaminergic-therapy-for-patients-with-restless-legs-syndrome/ Wed, 29 Apr 2026 14:23:06 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ferric-derisomaltose-and-dopaminergic-therapy-for-patients-with-restless-legs-syndrome/ This clinical trial is focused on studying the effects of a treatment for Restless Legs Syndrome (RLS), a condition that causes an uncontrollable urge to move the legs, usually due to uncomfortable sensations. The study will explore the use of a medication called ferric derisomaltose, which is a form of iron given through an injection or infusion. This treatment will be tested alone or in combination with dopaminergic therapy, which involves medications that affect dopamine, a chemical in the brain that helps control movement.

The purpose of the study is to investigate how iron supplementation or a placebo, with or without dopaminergic therapy, affects the symptoms of RLS. Participants will receive either the iron treatment or a placebo, and some may also receive dopaminergic therapy. The study will monitor changes in the severity of RLS symptoms over time. Participants will be given the treatment through an intravenous infusion, which means the medication is delivered directly into a vein.

Throughout the study, various health indicators will be monitored, including blood tests to check levels of iron and other substances in the body. Some participants may also undergo an MRI scan, a type of imaging test, to look at iron content in a specific part of the brain. The study aims to provide insights into how these treatments can help manage RLS symptoms and improve the quality of life for those affected by this condition.

]]>